Clinical Application Study of 123IMetaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

What this Trial Is About

This research aims to assess the diagnostic accuracy of two imaging methods, 123I-MIBG SPECTCT and somatostatin receptor SSTR PET, in Chinese children suspected or confirmed to have neuroblastoma NB. It focuses on determining the sensitivity and specificity of each imaging technique alone and combined for initial cancer staging and detecting relapses or metastases. The study also explores whether SSTR-targeted PET can identify NB lesions that do not absorb MIBG and help select candidates for peptide-receptor radionuclide therapy PRRT. The study includes pediatric patients up to 18 years old undergoing routine NB evaluation. They will receive both 123I-MIBG SPECTCT and SSTR PETCT or PETMRI imaging. For 123I-MIBG, patients receive thyroid protection with Lugols iodine and an intravenous radioactive tracer, followed by whole-body and focused imaging. The SSTR PET involves intravenous injection of 68Ga-DOTA-TATE followed by whole-body PETCT or PETMRI scanning. Sedation is used as needed for motion control during imaging. Participants will be monitored through clinical follow-up and imaging results correlated with pathology and clinical course over 24 months. Researchers will measure standardized uptake values SUVmean, SUVmax, SUVpeak at baseline and six months to evaluate tumor activity. The study aims to provide detailed imaging insights for better NB diagnosis, staging, treatment planning, and response evaluation in Chinese children.

Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma